Voyager Therapeutics (VYGR) Tops Q2 EPS by 6c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.51), $0.06 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.85 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c